Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • C. Morath - , Heidelberg University  (Author)
  • B. Schmied - , Heidelberg University  (Author)
  • A. Mehrabi - , Heidelberg University  (Author)
  • J. Weitz - , Heidelberg University  (Author)
  • J. Schmidt - , University Hospital Heidelberg (Author)
  • J. Werner - , Heidelberg University  (Author)
  • M. W. Buchler - , Heidelberg University  (Author)
  • M. Morcos - , Endocrinology Department Hamburg (Author)
  • P. P. Nawroth - , Heidelberg University  (Author)
  • V. Schwenger - , Heidelberg University  (Author)
  • B. Doehler - , Heidelberg University  (Author)
  • G. Opelz - , Heidelberg University  (Author)
  • M. Zeier - , Heidelberg University  (Author)

Abstract

Renin-angiotensin system blockade retards the progression of diabetic and non-diabetic chronic kidney disease of the native kidneys. Though most patients suffer from a significant renal insufficiency (chronic kidney disease stage III) and a concomitant heart disease after renal transplantation, there is up to now no evidence supporting the use of inhibitors of the renin-angiotensin system in these patients. We wish to summarize the available evidence on the use of inhibitors of the renin-angiotensin system after renal transplantation. We specifically discuss potential beneficial as well as adverse effects of a renin-angiotensin system blockade. In addition, we review their influence on morphologic and biochemical markers as well as on renal function, graft and patient survival after renal transplantation.

Details

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalClinical Transplantation
Volume23
Issue numberSuppl 21
Publication statusPublished - Dec 2009
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 19930314

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Angiotensin-converting enzyme inhibitor, Angiotension II type 1 receptor blocker, Chronic allograft dysfunction, Renal transplantation